Everest vs RenaissanceRe
EG and RNR side by side, both in fire, marine, and casualty insurance. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EG and RNR compare
Everest and RenaissanceRe are about the same size, with market caps of $15.8B and $14.3B.
On earnings, Everest is cheaper: it trades at 9.0× trailing earnings, against 10.0× for RenaissanceRe.
Everest grew revenue faster over the last twelve months (−8.7% versus −20.9% for RenaissanceRe).
RenaissanceRe keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 11.7% at Everest.
Both pay dividends: Everest yields 1.4% and RenaissanceRe 0.35%.
Everest scores higher on the StockData Score (13 against 9 for RenaissanceRe), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EG | RNR |
|---|---|---|
| Size and price | ||
| Market cap | $15.8B | $14.3B |
| Share price | $427.19 | $353.62 |
| Change, 1 year | 31.4% | 33.0% |
| Change, 5 years | 59.9% | 116% |
| Beta (5Y) | 0.40 | 0.23 |
| Employees | 3,064 | 1,040 |
| StockData Score | ||
| Total score | 13 (better) | 9 |
| Valuation score | 6 (better) | 2 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 4 (better) |
| Health score | 0 | 0 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 9.0× (better) | 10.0× |
| P/S | 1.0× (better) | 1.5× |
| P/B | 1.1× (better) | 1.3× |
| EV/EBITDA | – | 4.5× |
| PEG | 0.25 | – |
| Fair value | $595.20 | $339.46 |
| Margin of safety | 28.2% (better) | −4.2% |
| Growth | ||
| Revenue growth (TTM) | −8.7% (better) | −20.9% |
| Revenue growth, 5Y average | 12.8% | 20.0% (better) |
| Net income growth (TTM) | 243% (better) | −9.7% |
| EPS growth (TTM) | 256% (better) | −1.7% |
| EPS growth, 5Y average | 24.2% | 29.6% (better) |
| Profitability | ||
| Net margin | 11.7% | 16.2% (better) |
| Return on equity | 12.8% | 13.7% (better) |
| Financial health | ||
| Altman Z-score | 0.86 (better) | 0.68 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.4% (better) | 0.35% |
| Payout ratio | 16.7% | 4.4% |
| Years of dividend growth | 4 | – |
| Dividend growth, 5Y average | 5.2% | – |
| Buyback yield | 10.1% | 11.7% (better) |
| Shareholder yield | 11.5% | 12.1% (better) |
| Ownership | ||
| Held by institutions | 105% | 103% |
| Held by insiders | 1.6% | 2.4% |
| Insider net buying, 12 months | −$3.4M (better) | −$16.2M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 4.2% | 3.0% |
Go deeper
- EG stock overview
- EG income statement
- EG valuation and score
- RNR stock overview
- RNR income statement
- RNR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.